BR112023002031A2 - Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos - Google Patents

Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos

Info

Publication number
BR112023002031A2
BR112023002031A2 BR112023002031A BR112023002031A BR112023002031A2 BR 112023002031 A2 BR112023002031 A2 BR 112023002031A2 BR 112023002031 A BR112023002031 A BR 112023002031A BR 112023002031 A BR112023002031 A BR 112023002031A BR 112023002031 A2 BR112023002031 A2 BR 112023002031A2
Authority
BR
Brazil
Prior art keywords
spiropiperidiny
derivatives
heteroaryl substituted
pharmaceutical uses
present
Prior art date
Application number
BR112023002031A
Other languages
English (en)
Inventor
Bushaboina Mallesh
Chen Xin
Kim Cheung Atwood
James Culshaw Andrew
Brian Hurley Timothy
LABBE-GIGUERE Nancy
Miltz Wolfgang
Orain David
Jayprakash Patel Tajesh
Rajagopalan Srinivasan
Roehn Till
Andrew Sandham David
Thoma Gebhard
Bhanudasji Tichkule Ritesh
Wälchli Rudolf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112023002031A2 publication Critical patent/BR112023002031A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

DERIVADOS DE ESPIROPIPERIDINILA SUBSTITUÍDOS POR HETEROARILA E USOS FARMACÊUTICOS DOS MESMOS. A presente invenção refere-se a um composto da fórmula (I) ou um sal farmaceuticamente aceitável do mesmo; (I) em que R1 R2, R4 e X1 são como definidos na presente invenção, um método para fabricar os compostos da invenção e seus usos terapêuticos. A presente invenção proporciona adicionalmente uma combinação de agentes farmacologicamente ativos e uma composição farmacêutica.
BR112023002031A 2020-08-14 2021-08-12 Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos BR112023002031A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20191191 2020-08-14
PCT/IB2021/057427 WO2022034529A1 (en) 2020-08-14 2021-08-12 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
BR112023002031A2 true BR112023002031A2 (pt) 2023-03-07

Family

ID=72088005

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002031A BR112023002031A2 (pt) 2020-08-14 2021-08-12 Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos

Country Status (20)

Country Link
US (2) US11708366B2 (pt)
EP (1) EP4196478A1 (pt)
JP (1) JP2023537357A (pt)
KR (1) KR20230051227A (pt)
CN (1) CN116157404A (pt)
AR (1) AR123241A1 (pt)
AU (2) AU2021325431B2 (pt)
BR (1) BR112023002031A2 (pt)
CA (1) CA3185469A1 (pt)
CL (1) CL2023000418A1 (pt)
CO (1) CO2023002940A2 (pt)
CR (1) CR20230125A (pt)
DO (1) DOP2023000028A (pt)
EC (1) ECSP23017158A (pt)
IL (1) IL299091A (pt)
MX (1) MX2023001725A (pt)
PE (1) PE20230855A1 (pt)
TW (1) TW202220990A (pt)
UY (1) UY39377A (pt)
WO (1) WO2022034529A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11708366B2 (en) * 2020-08-14 2023-07-25 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998834A (en) 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
JPWO2003028732A1 (ja) 2001-09-28 2005-01-13 協和醗酵工業株式会社 受容体拮抗剤
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
CN101835741A (zh) 2007-09-04 2010-09-15 比奥里波克斯公司 用于炎症治疗的双芳香族化合物
WO2011110824A1 (en) 2010-03-12 2011-09-15 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
JP2013515033A (ja) 2009-12-21 2013-05-02 ノバルティス アーゲー オレキシン受容体アンタゴニストとしてのジアザ−スピロ［５．５］ウンデカン類
MY162132A (en) 2010-06-23 2017-05-31 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
CA2807051A1 (en) 2010-08-10 2012-02-16 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US8551982B2 (en) 2011-03-14 2013-10-08 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
SG10201801668WA (en) 2011-06-10 2018-03-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
EP2734516B1 (en) 2011-07-19 2015-06-17 Boehringer Ingelheim International GmbH Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
LT2786996T (lt) 2011-11-29 2017-01-10 Ono Pharmaceutical Co., Ltd. Purinono darinio hidrochloridas
JP6080227B2 (ja) 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するためのベンゾジオキサン
JP6080226B2 (ja) 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc INHIBITORS OF BRUTON TYROSINE KINASE
EP2885285B1 (en) 2012-07-17 2016-10-19 Boehringer Ingelheim International GmbH Pyrazole drivatives which inhibit leukotriene production
WO2014039899A1 (en) 2012-09-10 2014-03-13 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
EP2951179B1 (en) 2013-02-04 2020-03-11 Merck Patent GmbH Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
CA2905340C (en) 2013-03-12 2022-05-31 Celtaxsys, Inc. Low dose oral formulations of acebilustat
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
WO2014152518A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
RS55770B1 (sr) 2013-04-25 2017-07-31 Beigene Ltd Fuzionisana heterociklična jedinjenja kao inhibitori protein kinaze
EP3022194B1 (en) 2013-07-15 2017-05-17 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
JP6353899B2 (ja) 2013-07-15 2018-07-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成の阻害剤
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EA201691169A1 (ru) 2013-12-05 2016-09-30 Асерта Фарма Б.В. Терапевтическая комбинация ингибитора pi3k и ингибитора btk
PL3083564T3 (pl) 2013-12-20 2018-12-31 Novartis Ag Pochodne kwasu heteroarylobutanowego jako inhibitory LTA4H
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
PE20190710A1 (es) 2014-10-24 2019-05-17 Bristol Myers Squibb Co Compuestos de indol carboxamida utiles como inhibidores de cinasas
CN107108556B (zh) 2014-11-03 2020-09-29 艾欧米制药有限公司 药用化合物
MX2017006513A (es) 2014-11-21 2018-04-11 Esteve Labor Dr Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
WO2016105531A1 (en) 2014-12-24 2016-06-30 Philip Nunn Site specific dosing of a btk inhibitor
GB201507753D0 (en) 2015-05-06 2015-06-17 Biolipox Ab New compounds and uses
EA039006B1 (ru) 2015-06-03 2021-11-19 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
MA42510A (fr) 2015-06-10 2018-06-06 Biogen Ma Inc Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
EP4014977A1 (en) 2015-11-04 2022-06-22 Merck Patent GmbH Pyrimidine compounds with btk inhibitory activity for use in treating cancer
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN107406453B (zh) 2016-01-05 2018-12-28 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的结晶形式及其制备方法
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
US11708366B2 (en) * 2020-08-14 2023-07-25 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof

Also Published As

Publication number Publication date
WO2022034529A1 (en) 2022-02-17
CA3185469A1 (en) 2022-02-17
KR20230051227A (ko) 2023-04-17
AR123241A1 (es) 2022-11-09
JP2023537357A (ja) 2023-08-31
AU2024200054A1 (en) 2024-01-25
EP4196478A1 (en) 2023-06-21
MX2023001725A (es) 2023-02-22
AU2021325431B2 (en) 2024-01-18
DOP2023000028A (es) 2023-03-15
US11708366B2 (en) 2023-07-25
CO2023002940A2 (es) 2023-03-17
PE20230855A1 (es) 2023-05-29
UY39377A (es) 2022-03-31
US20240043425A1 (en) 2024-02-08
ECSP23017158A (es) 2023-04-28
CR20230125A (es) 2023-05-11
IL299091A (en) 2023-02-01
AU2021325431A1 (en) 2023-01-19
US20220048909A1 (en) 2022-02-17
CN116157404A (zh) 2023-05-23
TW202220990A (zh) 2022-06-01
CL2023000418A1 (es) 2023-09-29

Similar Documents

Publication Publication Date Title
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
BR112022025037A2 (pt) Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
BR112023002031A2 (pt) Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112015019369A2 (pt) derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BRPI0507830A (pt) derivados azabicìclicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BRPI0310032B8 (pt) derivados de benzoxazina, seus usos e seus processos de produção, e composição farmacêutica
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
BR112022021748A2 (pt) Compostos e composições para inibir a atividade de hif2a e seus métodos de uso
BR112023003832A2 (pt) Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos
BR112023024551A2 (pt) Análogos de triazolo-pirimidina para tratamento de doenças relacionadas à inibição de recq helicase de síndrome de werner (wrn)
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário